PubRank

S Vella

Author PubWeight™ 127.76‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000 7.81
2 Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998 7.53
3 A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998 7.00
4 Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000 6.49
5 Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1997 6.35
6 Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA 1996 5.29
7 Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998 4.61
8 Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA 1998 4.42
9 Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group. JAMA 1994 2.56
10 In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J Infect Dis 1996 2.34
11 Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med 2003 2.30
12 High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001 2.03
13 Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. Int J Epidemiol 1997 1.97
14 Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 1998 1.81
15 A three-year diagnostic and epidemiological study on viral infantile diarrhoea in Rome. Epidemiol Infect 1988 1.57
16 SPECT during sleepwalking. Lancet 2000 1.54
17 The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS 1999 1.52
18 Epidemiology of AIDS dementia complex in Europe. AIDS in Europe Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1996 1.43
19 Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection. J Pediatr 1999 1.41
20 Survival differences in European patients with AIDS, 1979-89. The AIDS in Europe Study Group. BMJ 1994 1.41
21 False positives and false negatives: is the answer relatively simple? Acta Psychiatr Scand 2012 1.39
22 Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004 1.28
23 Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother 2000 1.18
24 Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med 2007 1.17
25 Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1997 1.14
26 A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group. AIDS 1996 1.08
27 Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS 2001 1.07
28 Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume. AIDS 2000 1.07
29 Vaginal transmission of HIV-1 in hu-SCID mice: a new model for the evaluation of vaginal microbicides. AIDS 2001 1.04
30 Antigen-specific human T-cell hybridomas with helper activity. Proc Natl Acad Sci U S A 1982 1.02
31 Longitudinal human immunodeficiency virus type 1 load in the italian seroconversion study: correlates and temporal trends of virus load. J Infect Dis 1999 1.01
32 ISSQoL: a new questionnaire for evaluating the quality of life of people living with HIV in the HAART era. Qual Life Res 2006 0.97
33 HIV-related morbidity and mortality in patients starting protease inhibitors in very advanced HIV disease (CD4 count of < 50 cells/microL): an analysis of 338 clinical events from a randomized clinical trial. HIV Med 2002 0.95
34 Outbreak of rotavirus gastroenteritis among premature infants. Br Med J (Clin Res Ed) 1981 0.91
35 Induction-maintenance antiretroviral therapy: proof of concept. AIDS 1998 0.90
36 Swelling of the third nerve in a child with transient oculomotor paresis: a possible cause of ophthalmoplegic migraine. Neuropediatrics 2000 0.90
37 Antibody reactive in antibody-dependent cell-mediated cytotoxicity following influenza virus vaccination. J Med Virol 1980 0.90
38 High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. J Infect Dis 1997 0.89
39 The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy. HIV Med 2009 0.89
40 Deregulation of the CD95/CD95L system in lymphocytes from patients with primary acute HIV infection. AIDS 2000 0.88
41 Metformin in type 1 diabetes reduces insulin requirements without significantly improving glycaemic control. Reply to Schatz H [letter]. Diabetologia 2010 0.87
42 HIV-HCV RNA loads and liver failure in coinfected patients with coagulopathy. Haematologica 1999 0.87
43 Tuberculosis among European patients with the acquired immune deficiency syndrome. The AIDS in Europe Study Group. Tuber Lung Dis 1996 0.87
44 Condom use for preventing the spread of HIV/AIDS: an ethical imperative. J R Soc Med 2000 0.87
45 Human PrP90-231-induced cell death is associated with intracellular accumulation of insoluble and protease-resistant macroaggregates and lysosomal dysfunction. Cell Death Dis 2011 0.86
46 Epidemiology of AIDS-related Kaposi's sarcoma in Europe over 10 years. AIDS in Europe Study Group. AIDS 1996 0.86
47 Expression of P-170 glycoprotein sensitizes lymphoblastoid CEM cells to mitochondria-mediated apoptosis. Biochem J 2001 0.86
48 HIV phenotype switching during antiretroviral therapy: emergence of saquinavir-resistant strains with less cytopathogenicity. AIDS 1997 0.86
49 Quality of life outcomes of combination zidovudine- didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients. AIDS 2000 0.86
50 Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (Invirase) treatment. J Med Virol 1997 0.85
51 Secretory immune response after nasal vaccination with live attenuated influenza viruses. Rhinology 1980 0.85
52 A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease. J Acquir Immune Defic Syndr Hum Retrovirol 1999 0.85
53 Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection. Antimicrob Agents Chemother 2000 0.85
54 Spontaneous and anti-Fas-induced apoptosis in lymphocytes from HIV-infected patients undergoing highly active anti-retroviral therapy. AIDS 2000 0.85
55 Adrenocorticotropin is a specific mitogen for mammalian myogenic cells. Dev Biol 1989 0.83
56 Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team. AIDS 1998 0.83
57 The effects of AZT and DDI on pre- and postimplantation mammalian embryos: an in vivo and in vitro study. AIDS Res Hum Retroviruses 1992 0.82
58 Correlation between changes in plasma HIV RNA levels and in plasma infectivity in response to antiretroviral therapy. AIDS Res Hum Retroviruses 1997 0.82
59 Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team. J Acquir Immune Defic Syndr 1999 0.82
60 AIDS dementia complex in the Italian National AIDS Registry: temporal trends (1987-93) and differential incidence according to mode of transmission of HIV-1 infection. J Neurol Sci 1996 0.82
61 Clinical implications of resistance to antiretroviral drugs. AIDS Clin Care 1997 0.81
62 Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma. Br J Cancer 2013 0.81
63 What to add in with metformin in type 2 diabetes? QJM 2010 0.80
64 Thymus volume correlates with the progression of vertical HIV infection. AIDS 1999 0.80
65 Mission now possible for AIDS fund. Nature 2001 0.80
66 Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials. Antiviral Res 1996 0.80
67 Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/microL). HIV Med 2004 0.80
68 Summary of the international consensus symposium on management of HIV, CMV and hepatitis virus infections. Antiviral Res 1998 0.80
69 Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1998 0.79
70 HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART. J Acquir Immune Defic Syndr 2001 0.79
71 Hepatitis B virus mother-to-child transmission among HIV-infected women receiving lamivudine-containing antiretroviral regimens during pregnancy and breastfeeding. J Viral Hepat 2014 0.79
72 Advances in the virology of HIV infections and implications for clinical management. AIDS Clin Care 1998 0.79
73 Markers of cell death-activation in lymphocytes of vertically HIV-infected children naive to highly active antiretroviral therapy: the role of age. J Allergy Clin Immunol 2001 0.79
74 Adherence and genotypic drug resistance mutations in HIV-1-infected patients failing current antiretroviral therapy. J Chemother 2011 0.78
75 Frequency and determinants of use of antiretroviral and prophylactic therapies against Pneumocystis carinii Pneumonia (PCP) before AIDS diagnosis in Italy. Eur J Epidemiol 1998 0.78
76 Immunological and virological markers in HIV infection. AIDS Clin Care 1995 0.77
77 A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection. J Infect Dis 1997 0.77
78 Interleukin-15 production by monocyte-derived dendritic cells and T cell proliferation in HIV-infected patients with discordant response to highly active antiretroviral therapy. Clin Exp Immunol 2004 0.77
79 Hospitalizations and costs of treatment for protease inhibitor-based regimens in patients with very advanced HIV-infection (CD4 < 50/mm(3)). HIV Clin Trials 2001 0.77
80 [PFAPA syndrome: periodic fever, adenitis, pharyngitis and aphthous stomatitis]. Schweiz Med Wochenschr 1997 0.76
81 HIV-1 coreceptor switch during 2 years of structured treatment interruptions. Eur J Clin Microbiol Infect Dis 2013 0.76
82 [Objective value of adenotonsillectomy in the child. A prospective study of incidence of tonsillitis, snoring, pulse oximetry and polysomnography and general development before and after adenotonsillectomy]. Praxis (Bern 1994) 1999 0.75
83 Agitated sleepwalking with fluoroquinolone therapy. Pediatr Infect Dis J 1999 0.75
84 Influenza vaccination with live-attenuated and inactivated virus-vaccines during an outbreak of disease. J Hyg (Lond) 1979 0.75
85 High rate of HIV isolation from plasma of asymptomatic patients through polyethylene glycol (PEG) treatment. J Acquir Immune Defic Syndr 1994 0.75
86 British HIV Association guidelines. Lancet 1998 0.75
87 Success hinges on support for treatment. Nature 2001 0.75
88 [Rubella immunity among unvaccinated young women (author's transl)]. Ann Sclavo 1982 0.75
89 Antimicrobial activity of a series of new 5-nitro-2-furaldehyde aminoacethydrazones. Chemotherapy 1972 0.75
90 Antimicrobial activity of 5-nitro-2-furaldehyde-N'-methyl-N-piperazino-acethydrazone, a new hydrosoluble nitrofuran derivative. Studies on in vivo chemotherapeutic activity. Chemotherapy 1973 0.75
91 A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection. AIDS Res Hum Retroviruses 2000 0.75
92 [Epidemiological news on infectious diseases]. Medicina (Firenze) 1989 0.75
93 Protease inhibitors and nucleosides: how many? when? An interview with Stefano Vella, MD. Interview by Mark Mascolini. J Int Assoc Physicians AIDS Care 1995 0.75
94 Structured treatment interruptions and treatment intensification. AIDS Clin Care 2000 0.75
95 Changes in apoptosis after interruption of potent antiretroviral therapy in patients with maximal HIV-1-RNA suppression. AIDS 2001 0.75
96 [Controversies concerning the use of zidovudine in the treatment of asymptomatic HIV+ subjects with a low number of CD4+ lymphocytes]. Medicina (Firenze) 1991 0.75
97 [Clinical picture of the onset of AIDS in 2911 adults in Italy]. Medicina (Firenze) 1989 0.75
98 [Decrease in notifications of AIDS dementia complex in 1989-1990 in Italy: possible role of the early treatment with zidovudine]. Medicina (Firenze) 1991 0.75
99 Facing an emerging threat: the spread of HIV resistance. J HIV Ther 2001 0.75
100 [Epidemiological news on infectious diseases]. Medicina (Firenze) 1989 0.75
101 A case for proactive switching? AIDS Clin Care 1999 0.75
102 Estimates of the virological benefit of antiretroviral therapy are both assay- and analysis-dependent. AIDS 1998 0.75
103 The absence of HIV mutations in cerebrospinal fluid and in peripheral blood mononuclear cells during a regimen containing Trizivir plus tenofovir. J Chemother 2009 0.75
104 Human T cell hybridomas with tetanus-toxoid-specific helper activity. Curr Top Microbiol Immunol 1982 0.75
105 [AIDS in Italy up to November 30, 1988]. Medicina (Firenze) 1989 0.75
106 HIV eradication revisited. Expert Opin Investig Drugs 2000 0.75
107 AIDS 1999. Clinical treatment: overview. AIDS 1999 0.75
108 New antiretroviral therapy guidelines. AIDS Clin Care 1996 0.75
109 Update on HIV protease inhibitors. AIDS Clin Care 1995 0.75
110 Saquinavir delays the emergence of zidovudine resistance in HIV-1 seropositive patients treated with combination therapy. J Med Virol 1998 0.75
111 Access to HIV/AIDS care and treatment in the south of the world. AIDS 2001 0.75
112 [Epidemiological news on infectious diseases]. Medicina (Firenze) 1989 0.75
113 Antimicrobial activity of 5-nitro-2-furaldehyde-N'-methyl-N-piperazinoacethydrazone, a new hydrosoluble nitrofurane derivative. I. In vivo antibacterial activity. Chemotherapy 1972 0.75
114 The use of protease inhibitors. A sampling of opinions. Interview by Deborah J Cotton. AIDS Clin Care 1996 0.75